Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...

Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...

This article was reviewed by Felix Gussone, MD. Understanding the Testosterone-Acne Connection If you thought acne breakouts ...

Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...

Preclinical study showed PDIA1 and PDIA5 protect cells from oxidative stress, maintain mitochondrial function, and are ...

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the ...